MEI Pharma: MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

(marketscreener.com) - MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway -https://www.marketscreener.com/quote/stock/MEI-PHARMA-INC-12212540/news/MEI-Pharma-Board-of-Directors-Aligns-on-Strategy-to-Advance-Voruciclib-and-ME-344-46413824/?utm_medium=RSS&utm_content=20240411